8:15 am Virtual Coffee Room Opens
Targeting Solid Tumors with Combination Approaches
8:30 am Harnessing the Next Wave of Immune Checkpoints to Enhance Cell Therapy in Solid Tumors
9:00 am Leveraging Immune-Adjuvants to Enhance T Cell Therapy in Solid Tumors
9:30 am Using Adaptive’s Immune Medicine Platform to Advance Cell Therapies in Oncology
Synopsis
- Adaptive’s Immune Medicine Platform leverages proprietary chemistry, computational biology, and machine learning to read and understand patient’s immune systems.
- Adaptive has developed a best-in-class, high-throughput T cell receptor (TCR) screening platform that allows the discovery of naturally-occurring, potent, ultra-low frequency TCRs with differentiated therapeutic potential.
- The Adaptive TruTCR discovery engine has allowed the selection and characterization of several high avidity TCRs against clinically relevant targets, demonstrating improved cytolysis relative to benchmark TCRs and preliminary promising safety profile.
10:00 am Developing Parallel CAR-T for Increased Efficacy
10:30 am Morning Refreshments & Speed Networking
Harnessing Natural Immune Biology to Inform Multi-Targeted Strategies
Chair: Madan Jagasia
11:30 am Targeting the Solid Tumor Microenvironment with Synergistic Therapy to Enhance T Cell Infiltration and Survival
12:00 pm Leveraging TILs to Engage Solid Tumors as a Natural Multi-Targeted Approach
12:20 pm CRISPR/Cas9 Engineered TIL for Supercharged T Cell Function
12:40 pm Expert Panel Q&A: Challenges, Strengths and Next Steps in Advancing TIL Therapies
1:00 pm Lunch & Networking
Leveraging Logic to Enhance Tumor-Specificity
1:30 pm Developing Engineering Solutions to Promote CAR-T Cell Safety and Function in the Tumor Microenvironment
2:00 pm Developing Co-Stimulatory Domains to Create Robust, Target Cell-Specific Activation
2:30 pm Tmod: A Cell Therapy That Exploits Loss-of-Heterozygosity to Specifically Kill Tumor Cells
3:00 pm Pharmacological Control of CAR T Cell Therapies
3:30 pm Afternoon Networking
Tuned Tumor Killing with Synergistic Therapy
4:00 pm Targeting Multiple Antigens with Antibody-Redirected CARs Sequentially vs. Simultaneously
4:30 pm Employing Viral Combinations to Make Solid Tumors Vulnerable to CAR-T Therapy
5:00 pm Suppressing the Tumor Microenvironment with Combination Therapy to Enhance Anti-Tumor Efficacy in Solid Tumor Indications
5:30 pm Chair’s Closing Remarks
5:45 pm Close of Summit
On-Demand Content
Richard Boyd
CSO
Cartherics Ltd.
Sculpting the Immune System Through Multi-Moiety Therapy
- Investigating the therapeutic effects of infusion of multiple cell types derived from gene-edited iPSC cells; how important is histocompatibility? What role for combination with antibody modalities?
- Describing the immune response and mechanistic rationale behind multi cell-type infusion, the role of each modality, and their multiplexed effects in vivo; how best to engage the patients endogenous immune system as a complementary anti-cancer defence?
- Discussing clinical, manufacturing and regulatory challenges in implementing multi-moiety strategies such as toxicity, and
understanding the additive effects of different cell types; expect the unexpected